Press Releases Merck KGaA

Equities

MRK

DE0006599905

Pharmaceuticals

Market Closed - Xetra Other stock markets 16:35:13 11/07/2025 BST			After hours 20:58:03
112.80 ^EUR	-1.44%		113.30	+0.44%

07-07	European share rise on tech, banks boost with focus on US trade negotiations	RE
07-07	Frankfurt Stocks Close: DAX Defies US Tariff Threats Ahead of Deadline	DP

Press Releases

Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	07-08	EQ
Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	07-07	EQ
Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	07-04	EQ
Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	07-03	EQ
Curiosity Cube Debuts in Africa and Expands Global STEM Mission	06-23	AQ
Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	06-13	EQ
Merck Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025	06-13	AQ
Merck KGaA: Correction of a release from 05/06/2025 according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	06-13	EQ
Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	06-10	EQ
Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	06-05	EQ
Merck : Pimicotinib Demonstrates Best-in-Class Potential with Significant Efficacy and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumor	05-28	PU
Merck Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with CLE and SLE with Active Lupus Rash	05-22	AQ
Merck : Collaboration with imec to Develop Disruptive Microphysiological Systems Platform	05-20	PU
Merck : Prospectus - C-031064	05-17	PU
Merck : Darmstadt, Germany, Continues to Deliver Growth in Turbulent Times	05-15	PU
Proteomics Market worth $60.5 billion by 2029 driven by Rising Tech Innovations	05-14	AQ
Merck : Annual General Meeting Approves All Agenda Items	04-25	PU
Merck KGaA: Merck confirms late-stage discussions with SpringWorks Therapeutics, Inc. on potential acquisition	04-24	EQ
Pan African Visions Journalists Win Prestigious Merck Foundation Awards for Excellence in Health and Social Reporting The recognition came during the 2024 Merck Foundation Media Recognition Awards, held virtually on April 10, 2025, under the patronage of Senator Dr. Rasha Kelej, CEO of the Merck Foundation	04-13	AQ
Merck KGaA, Zebra Technologies partner on product verification platform	03-28	AQ
Merck : Darmstadt, Germany, Exercises Option for Commercialization of Pimicotinib	03-28	PU
DD: Merck KGaA: Freifrau Helene von Roeder, buy	03-27	EQ
DD: Merck KGaA: Peter Guenter, buy	03-27	EQ
DD: Merck KGaA: Dr. Matthias Heinzel, buy	03-27	EQ
DD: Merck KGaA: Belén Garijo Lopez, buy	03-27	EQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

MERCK : Economic turbulence prompts recalibrations

May 19, 2025 at 08:54 am

Merck KGaA to Buy Springworks for $3.9B

April 28, 2025 at 06:25 pm